<DOC>
	<DOCNO>NCT01212913</DOCNO>
	<brief_summary>Primary Objective : To demonstrate non-inferiority hemoglobin A1c ( HbA1c ) control six month basal plus one biphasic insulin regimen . Secondary Objective : To demonstrate favorable outcome basal plus biphasic insulin come compare hemoglobin A1c ( HbA1c ) target goal achievement non-hypoglycemic event take account .</brief_summary>
	<brief_title>Comparison Insulin Glargine/Insulin Glulisine Regimen Insulin Aspart/Insulin Aspart Protamine 30/70 Type 2 Diabetes Mellitus Patients ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Protamines</mesh_term>
	<criteria>Inclusion criterion : 1 . Suboptimally control Type 2 Diabetes Mellitus ( T2DM ) patient treat insulin glargine minimum 3 month : Suboptimal : HbA1c level &gt; 7 % fast blood glucose &lt; 130mg/dL 2 . Male Female ≥18 year old 3 . Body Mass Index ( BMI ) &lt; 40 4 . 10 % ≥HbA1c ≥7 % 5 . If take Oral antidiabetic ( OADs ) , must stable dose least 1 month 6 . Patients willing sign data release consent form Exclusion criterion : 1 . Diabetes T2DM 2 . Enrolled clinical trial 3 . Previous treatment insulin insulin glargine 4 . Treatment Glucagonlike peptide1 ( GLP1 ) receptor agonist Di Peptidyl Peptidase 4 ( DPPIV ) inhibitors 5 . Pregnant lactate woman 6 . Contraindicated Lantus ( insulin glargine ) / Apidra ( insulin glulisine ) / Novomix 30 ( insulin aspart ) 7 . Treatment systemic corticoid steroid within last 3 month prior study enter 8 . Treatment investigational product within last 3 month prior study entry The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>